Sarcopenic Obesity Clinical Trial
Official title:
Prevalence of Sarcopenic Obesity Among Community Dwelling Elderly: A Pilot Study
Sarcopenic obesity (SO) is a geriatric syndrome, characterized by reduced muscle mass and function, and increase in body fat. It is classified as a new category of obesity in elderly. It found to be associated with higher risk of physical disability, hospitalization, metabolic syndrome, cardiovascular disorders and mortality. According to the United Nations Economic and Social Commission for Asia and The Pacific's (UNESCAP) 2016 population data, Malaysians aged sixty and above contribute to 9.5% of the population. The aging individuals are estimated to reach 23.5% of the population by 2050. In the matter of human health, SO increases the risk of falls and fracture, deteriorates the performance of activities of daily living, enhances the risk of getting multiple health-related outcomes and results in physical disability. Eventually, the quality of life is adversely affected. In financial terms, SO cause significant burden to health care systems. Both hospitalization and cost of care during hospitalization are increased. Therefore, study of SO has experienced a revitalized research interest due to its negative impact on public health. In addition, there is significant lack of literature related to prevalence of SO in community-dwelling elderly in Malaysia, hence, a need to investigate this phenomenon.
Pilot study design was employed to determine the prevalence of sarcopenic obesity among
community-dwelling elderly living in Kajang, Selangor. The sampling method used for
recruitment of subjects was non-probability, convenient sampling. Sample size was calculated
based on the work carrrid by Viechtbauer in 2015.
n=(In (1-y))/(In (1-π) ) where n = sample size π = problem probability y = level of
confidence
The population of Kajang is approximately 428,131. The elderly population made up of about
9.5% of the total population in Malaysia based on the UNESCAP's 2016 population data. With
confidence interval of 95% and margin of error 5%, The targeted sample size for this research
study was set to be 59. Investigators recruited 65 subjects.
Measurements of the four diagnostic criteria for sarcopenic obesity were:
1. Muscle mass (skeletal muscle index - SMI) 2. Body Fat (percent body fat). Bioelectrical
Impedance Analysis (BIA) device was used to measure muscle mass and percent body fat 3.
Muscle strength (handgrip strength), and 4. Physical performance (usual gait speed).
The weight and height of all subjects were measured as BIA needed this data to quantify the
muscle mass. Body weight and height were measured to the nearest 0.1kg and 0.01m using the
calibrated stadiometer with electronic weighing scale. Before the measurements, the subjects
were required to remove their footwear, accessories and excessive clothing, if any. After
getting the readings for weight and height, body mass index (BMI) was calculated, to the
nearest 0.01kg/m². Next, bioelectrical impedance analysis (BIA) device was utilized to
analyze the subjects' body composition (SMI & percent body fat). Before body composition
analysis, all subjects were informed to fast overnight and not to eat and drink anything
before analyzing was carried out. All the respective subjects weight and height was inserted
into the BIA device (Inbody S10 Body Composition Analyzer). The device operates with six
different frequencies (1kHz, 5kHz, 50kHz, 250kHz, 500kHz, 1000kHz) at five segments of body,
which are right arm, left arm, trunk, right leg and left leg. SMI, which is the
height-adjusted appendicular skeletal muscle mass (ASM) of an individual was used to detect
sarcopenia in the study subjects from the aspect of muscle mass. SMI (kg/m2) was calculated
by dividing ASM (kg) with subject's height (m2). For ASM, the lean muscle mass of four limbs
were added up. Scientific calculator was used to obtain the ASM and SMI of the subjects as
these were not provided in the body analysis result sheet. Both the ASM and SMI were
quantified to the nearest 0.01kg and 0.01 kg/m2 respectively.
Before starting body composition analysis, subjects were positioned in seated posture and
touch type electrodes were fixed on their four limbs. They were asked to rest their forearms
on the arm rest and kept their legs apart. Their feet must be flat on the floor. For
electrode placements, hand electrodes will be placed over the index (black) and middle (red)
fingers for both hands, whereas foot electrodes will be placed over the ankles (red for
medial side; black for lateral side) for both feet. Alcohol swap was used to wipe subjects'
ankles to moisture the skin over that area. Once the analysis began, the subjects were
instructed to avoid any body movement and not to fall asleep throughout the process. The
entire analysis process normally took 2-3 minutes.
Handgrip dynamometer (HGD) was used to evaluate the subjects' handgrip strength (HS). The
model of HGD equipped was Jamar® Hydraulic Hand Dynamometer. The measurements were done for 3
times to get the average readings. HS was measured to the nearest 0.01kg. Standardized
positioning recommended by the American Society of Hand Therapies (ASHT) were employed:
subjects in sitting position with back supported, shoulders adducted, elbow flexed at 90°,
forearm and wrist in neutral position. Subjects were instructed to hold the dynamometer and
exert maximum force by dominant hand forcefully for 3 seconds. Demonstration was given before
participants performed the maneuver. 1 minutes rest interval was given between each trial to
prevent muscle fatigue.
Usual gait speed (GS) was measured by 6 meters walk test (6 MWT), as suggested by EWGSOP to
assess the subjects' physical performance. Gait speed (GS) (meters/second) was calculated by
dividing distance walked (m) with the time taken to finish the walkway (in seconds). Subjects
were required to repeat the test for three times to obtain average reading. Time taken to
complete the walkway was measured using timer in mobile phone to the nearest 0.1 seconds,
whereas GS was measured to the nearest 0.1m/s. A walkway with distance of 10 meters was
measured using measuring tape. Green colour cones were being positioned at the both end
points of the walkway, with 2 and 8 meters marked with yellow colour cones. The first and
last 2 meters were used as acceleration and deceleration phase respectively. The subjects
were instructed to walk at their usual and comfortable pace. The timing was being started
when the toes of leading foot cross 2-meter mark, and stopped once 8-meter mark was crossed.
. The subjects were allowed to use assistive device, if any, during the gait test.
Demonstration was given before the test. Several precautions were taken throughout the test;
one of the researcher was walking half step behind the participants so their speed of walking
will not be influenced, both researcher and subject were not allowed to talk and researcher
must by the side of subjects to prevent them from falling. Besides, subjects were free to
stop the test if they felt any discomfort but no such instance was reported.
Diagnostic algorithm was used as the principal guideline for diagnosis of sarcopenia adapted
from Asian Working Group for Sarcopenia (AWGS) and European Working Group on Sarcopenia in
Older People 2 (EWGSOP2). According to recommendations by AWGS, the cut-off values for SMI
(kg/m2) are 7.00kg/m2 and 5.70 kg/m2 for male and female respectively were used to identify
low muscle mass. For muscle strength, values of <26.00kg for male and <18.00kg were
considered as low. In addition, poor physical performance was evaluated when the value for
gait speed is <0.8m/s and it is not gender-specific. To define obesity, American Society of
Bariatric Physicians (ASBP) suggested to use percent body fat of ≥25% for male and ≥30% for
female.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03119610 -
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
|
Phase 1/Phase 2 | |
Recruiting |
NCT03212391 -
WAVE Study- Walking and Aging in VErona Study
|
N/A | |
Recruiting |
NCT05289219 -
Effects of Physical Exercise on Sarcopenia After Bariatric Surgery
|
N/A | |
Completed |
NCT05143398 -
Nutritional Supplementation in Sarcopenic Obesity
|
N/A | |
Completed |
NCT04122638 -
Prevalence of Sarcopenia and Sarcopenic Obesity in Older Adults
|
||
Recruiting |
NCT05582668 -
Sarcopenia After Bariatric Surgery in Older Patients: A Cohort Study
|
||
Active, not recruiting |
NCT02379026 -
Lifestyle Modifications for the Treatment of Sarcopenic Obesity
|
N/A | |
Enrolling by invitation |
NCT05638035 -
Effects of Obesity on Rectus Femoris Muscle Thickness, Sarcopenia, Gait and Balance in Women
|
||
Recruiting |
NCT05477277 -
Adverse Outcomes and Mortality in Liver Transplant
|
N/A | |
Not yet recruiting |
NCT04597788 -
Efficacy of Protein Supplemented Very Low Calorie Meals on Weight Loss
|
N/A | |
Completed |
NCT04771377 -
Effect of Protein Supplementation and a Structured Exercise Program on Muscle in Women After Bariatric Surgery.
|
N/A | |
Recruiting |
NCT03347773 -
Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity
|
N/A | |
Active, not recruiting |
NCT04272073 -
A High-PRotein Mediterranean Diet and Resistance Exercise for Cardiac Rehabilitation
|
N/A | |
Recruiting |
NCT06320158 -
Dissecting the Molecular and Cellular Pathophysiology of Sarcopenic Obesity in the Elderly
|
||
Completed |
NCT03863379 -
Sarcopenic Obesity in Neurodisabilities
|
||
Recruiting |
NCT04221750 -
Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors
|
Phase 3 | |
Completed |
NCT05918159 -
Effects of Sarcopenia on General Health Status in Elderly: a Population-based Study
|
||
Completed |
NCT05029713 -
Sarcopenic Obesity in Liver Transplanted Patients
|
||
Completed |
NCT03370211 -
Resistance Training and Sarcopenic Obesity Elderly Women
|
N/A | |
Recruiting |
NCT05734755 -
Dietary Programme and Exercise Training in Combination or Separately on Managing Sarcopenic Obesity in Older Adults
|
N/A |